Japan Novel Drug Delivery System Market Size, Share, and COVID-19 Impact Analysis, By Route of Administration (Oral Drug, Injectable Drug, Pulmonary Drug, Transdermal Drug, and Others), By Mode of NDDS (Targeted, Controlled, and Modulated), and Japan Novel Drug Delivery System Market Insights, Industry Trend, Forecasts to 2035.

Japan Novel Drug Delivery System Market Insights Forecasts to 2035

• The Japan Novel Drug Delivery System Market Size is Expected to Grow at a CAGR of 6.4%   from 2025 To 2035
• The Japan Novel Drug Delivery System Market Size is Expected to Hold a Significant Share By 2035

According to a research report published by Spherical Insights & Consulting, The Japan Novel Drug Delivery System Market Size is Expected to hold a significant share By 2035, at a CAGR of 6.4% during the forecast period 2025-2035. The Japan novel drug delivery systems (NDDS) market is increasing due to the rise of targeted and personalized therapies. These systems are very promising as compared to traditional drug delivery methods, such as improved bioavailability, controlled release, and reduced side effects.

Market Overview

The Japan novel drug delivery system (NDDS) market defines a quickly evolving business that focuses on innovative technologies optimizing the targeted and controlled drug release of therapeutic agents. These technologies utilize various approaches, including nanoparticles, liposomes, and transdermal patches, for improving drug efficacy, minimizing side effects, and improving patient compliance. The positive aspects regarding the Japanese NDDS market are its superior R&D capabilities, top pharmaceutical companies, and positive regulatory climate. New opportunities lie in emerging fields such as ocular and implantable drug delivery systems, filling unmet medical needs. The major drivers of the market growth are Japan's demographic aging, which increases the incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. Nanostructure creation in nanotechnology and targeted therapy in individualized medicine propel the need for personalized drug delivery products. Government initiatives such as the Sakigake designation system aim to speed up the development and approval of new therapies, providing an encouraging environment for NDDS breakthroughs.

Report Coverage

This research report categorizes the market for the Japan novel drug delivery system market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan novel drug delivery system market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan novel drug delivery system market.

Driving Factors

The primary drivers of Japan's new drug delivery system (NDDS) market are a rapidly aging population and higher cases of chronic diseases such as cancer and diabetes that increase the need for advanced treatment. Advancements in nanotechnology, biotechnology, and personalized medicine also fuel further rapid innovation in drug delivery methods. Strong R&D infrastructure, government assistance with programs such as the Sakigake fast-track program, and a strong pharmaceutical industry base also help drive the growth and development of the market.

Restraining Factors

The major inhibiting elements of the novel drug delivery system market of Japan are exorbitant development costs, lengthy regulatory processes, insufficient patient awareness of state-of-the-art treatments, and mass production hassle. These can work as hindrances to the take-up and slow down the growth rate of the market.

Market Segmentation

The Japan novel drug delivery system market share is classified into route of administration and mode of NDDS.

• The injectable drug segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan novel drug delivery system market is segmented by route of administration into oral Drug, injectable drug, pulmonary drug, transdermal drug, and others. Among these, the injectable drug segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to intravenous, intramuscular, and subcutaneous administration of drugs. Injectable administration is used regularly in the case of drugs with low oral bioavailability, targeted drug delivery, and local drug delivery at the site of action.

• The targeted segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan novel drug delivery system market is segmented by mode of NDDS into targeted, controlled, and modulated. Among these, the targeted segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is owing to increased medicine concentration at the point of action in the body; this medicine delivery ensures increased efficacy. The medicine is released at the point of action, which then binds to the diseased tissue.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan novel drug delivery system market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Tasei Kako Co Ltd.
• Hisamitsu Pharmaceutical Co., Inc.
• Terumo Corporation
• Astellas Pharma Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Nipro Corporation
• Antares Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Santen Pharmaceutical Co., Ltd.
• Others

Recent Developments:

• In February 2025, Astellas Pharma Inc. announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for Conditional Approval of avacincaptad pegol intravitreal solution (ACP), a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan novel drug delivery system market based on the below-mentioned segments

Japan Novel Drug Delivery System Market, By Route of Administration

• Oral Drug
• Injectable Drug
• Pulmonary Drug
• Transdermal Drug
• Others

Japan Novel Drug Delivery System Market, By Mode of NDDS

• Targeted
• Controlled
• Modulated